Kari Ferver
Overview
Kari effectively represents clients in complex and fast-paced antitrust and litigation matters, particularly in the healthcare space. She works closely with clients and colleagues to assess difficult and novel legal issues and craft associated strategies. Kari regularly drafts substantive motions and complaints; prepares corporate representatives for depositions; and communicates with clients about litigation developments and industry updates.
Career & Education
- University of California, Irvine, B.A., summa cum laude, Criminology, Law & Society, 2006
- University of California, Irvine, M.A., Social Ecology, 2009
- University of California, Irvine School of Law, J.D., summa cum laude, 2021
- California
Kari's Insights
Client Alert | 2 min read | 06.27.24
As reported in earlier Client Alerts, on November 7, 2023, the Federal Trade Commission challenged 100 patents as improperly listed in the Food and Drug Administration’s “Approved Drug Products with Therapeutic Equivalence Evaluations” publication, commonly known as the Orange Book. The FTC sent warning letters to ten drug and medical device manufacturers identifying patents for inhalers, autoinjectors and anti-inflammatory multi-dose bottles that the FTC believes are improperly listed. In response, some manufacturers withdrew their patents, and others agreed to cap certain out-of-pocket costs for their drugs, resulting in a “victory lap” of media activity from the FTC in April.
Firm News | 2 min read | 05.30.24
Crowell & Moring Honors Recipients of 25th Annual George Bailey Public Service Awards
Blog Post | 05.10.24
Client Alert | 4 min read | 05.07.24
Insights
Kari's Insights
Client Alert | 2 min read | 06.27.24
As reported in earlier Client Alerts, on November 7, 2023, the Federal Trade Commission challenged 100 patents as improperly listed in the Food and Drug Administration’s “Approved Drug Products with Therapeutic Equivalence Evaluations” publication, commonly known as the Orange Book. The FTC sent warning letters to ten drug and medical device manufacturers identifying patents for inhalers, autoinjectors and anti-inflammatory multi-dose bottles that the FTC believes are improperly listed. In response, some manufacturers withdrew their patents, and others agreed to cap certain out-of-pocket costs for their drugs, resulting in a “victory lap” of media activity from the FTC in April.
Firm News | 2 min read | 05.30.24
Crowell & Moring Honors Recipients of 25th Annual George Bailey Public Service Awards
Blog Post | 05.10.24
Client Alert | 4 min read | 05.07.24
